Sabrina Sun Embraces Competitive Spirit to Make a Difference for Patients

Sabrina discusses her career journey and shares her perspective on how a competitive mindset can help deliver the best medicines to patients.

Pipette and petri dish on top of genetic screening results

BioMarin Scientists Helping Reclassify Genetic ‘Variants of Uncertain Significance’ to Improve Diagnosis of Hypochondroplasia

The holistic effort involving screening, data science and clinical evidence has the potential to help advance scientific understanding of hypochondroplasia and improve care.

BioMarin Announces Agreement to Acquire Inozyme Pharma

The deal will bring BioMarin an investigational enzyme replacement therapy for ENPP1 Deficiency, a rare, serious and progressive genetic condition with no currently approved treatments.

Breakthrough Science

We relentlessly pursue bold science to translate genetic discoveries into new medicines that advance the future of human health.

Learn More

Focus on Patients

We listen to and learn from patient communities to collaborate on solutions with the potential to help improve care.

Learn More

People-First Culture

Our talented and dedicated people represent the best the biotech industry has to offer and have helped shape a culture focused on working together to deliver for the patients we serve.

Learn More

BioMarin is a global biotechnology company with eight marketed products that treat life-threatening conditions.

Since our founding in 1997, we’ve applied our scientific expertise in understanding the underlying causes of genetic conditions to create transformative medicines, using a number of treatment modalities. Our approved medicines treat achondroplasia, severe hemophilia A and several rare inherited and lysosomal storage diseases. We’re also advancing an industry-leading pipeline of investigational medicines that are in various stages of clinical and preclinical development.

Learn More